Pregnenolone in the Management of Schizophrenia Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00174889|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : May 21, 2008
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: Pregnenolone||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy and Safety of Pregnenolone Augmentation in the Management of Schizophrenia Patients: a Randomised Double-Blind Placebo-Controlled Trial|
|Study Start Date :||January 2005|
|Actual Study Completion Date :||May 2007|
- The computerized Cambridge Neuropsychological Test Automated Battery (CANTAB).
- The Positive and Negative Syndrome Scale.
- The Scale for the Assessment of Negative Symptoms.
- The Calgary Depression Scale for Schizophrenia.
- The Hamilton Scale for Anxiety.
- Extrapyramidal Symptom Rating Scale.
- Barnes Akathisia Scale.
- Abnormal Involuntary Movement Scale.
- The Scale to assess Unawareness of Mental Disorder (SUMD, Amador, 1999).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00174889
|Sha'ar Menashe Mental Health|
|Hadera, Israel, 38814|
|Principal Investigator:||Michael S. Ritsner, MD, PhD||Sha’ar Menashe Mental Health Center|